Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene

1 Sept 2004

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastric Cancer Management and Outcomes
Share to Gastrointestinal Tumor Research and Treatment
Share to Vascular Malformations and Hemangiomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15565413
DOI: 10.1007/s00535-003-1409-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogenePMID 15565413Read ↗

Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Secondary KIT mutations: the GIST of drug resistance and sensitivitySemantic proximity Read ↗

CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.